

PRESS RELEASE

A potential new treatment for cancer supportive care and gastrointestinal diseases

Hoersholm – April 22, 2010:

7TM Pharma reports promising preclinical data in models of cancer therapy-induced gastrointestinal disease supporting the potential of TM30339, an analogue of a natural human hormone, in cancer supportive care and treating other gastrointestinal diseases.

TM30339 has demonstrated the potential to improve animal survival and mucositis outcome post X-ray irradiation potentially through a crypt survival led mechanism.

Christian E. Elling, Vice President of 7TM Pharma commented: "These preclinical data support that TM30339 may have the potential to treat diseases such as mucositis and inflammatory bowel diseases, while importantly presenting a different pharmacological and mechanistic approach when compared to current drugs and compounds in development. As we already have substantial clinical understanding of the safety and tolerability of TM30339, we intend to investigate the full potential of this compound in these indications".

7TM Pharma

Contact person:

Christian E. Elling

Tel: +45 3925 7777

Email: cee@7tm.com

About TM30339

TM30339 was discovered and developed by 7TM Pharma. TM30339 is a potent peptide analogue of a natural human hormone from the pancreas, which selectively stimulates the NPY Y4 receptor.

About cancer therapy and gastrointestinal diseases

Most chemotherapy and radiation based cancer treatments destroy a portion of the rapidly dividing epithelial cell lining of the digestive tract resulting in ulceration and inflammation of the oral cavity and the gut, a condition that is known as mucositis. Mucositis is thus a common and often debilitating complication of cancer treatment, which decreases the quality of life of affected patients, may lead to prolonged hospitalization, and may limit the dose and efficacy of the cancer treatment.

The incidence of mucositis varies with different cancer therapies, but may affect 40 – 100 % of subjects treated with certain antineoplastic agents or full body radiation.



April 22, 2010
Page 2 of 2

About 7TM Pharma

7TM Pharma is a biotech company focusing on the clinical development of drugs with a primary therapeutic focus on obesity, gastrointestinal diseases and with its partner Ortho-McNeil-Janssen Pharmaceuticals (a Johnson and Johnson company) inflammation. 7TM Pharma's approach is to actively seek licensing partners during early clinical development.

Please visit www.7tm.com to see where you can meet us and where we are to present these data.

7TM's investors include Novo A/S, Alta Partners, LD Pensions, Index Ventures, Scottish Widows Investment Partnership, Sofinnova Capital, SR One, Global Life Science Ventures and GIMV. For more information on 7TM Pharma, please visit www.7tm.com.